FDA warned Rxgoodusa that its website sells unapproved, misbranded opioid and benzodiazepine drugs to U.S. consumers without prescriptions.
What happened
FDA reviewed www.rxgoodusa.com and found it offering tramadol and diazepam products for sale to U.S. consumers with claims that they treat pain, seizures, anxiety, and other conditions. FDA said the drugs are unapproved new drugs and misbranded, and it noted a prior August 1, 2025 warning letter to the same operation under www.usaquickmeds.com for similar violations.
What FDA found
The website offers unapproved new drugs, including tramadol and diazepam, without FDA-approved applications.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The drugs' labeling lacks adequate directions for safe use by a layperson, so they are misbranded.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]The website offers prescription drugs without requiring a prescription, which misbrands them.
FD&C Act sections 503(b)(1) and 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]FDA said similar violations continued after an August 1, 2025 warning letter.
What FDA wants
FDA tells Rxgoodusa to stop offering any unapproved and misbranded drugs to U.S. consumers and to respond in writing within 15 working days describing corrective steps and how it will prevent recurrence.
Who should pay attention
- online pharmacies and websites selling prescription drugs
- platforms and payment processors that host or process sales for such sites
- consumers and clinicians dealing with opioid or benzodiazepine risks
This is a summary. Read the original letter on fda.gov.